Tibulizumab

Phase 2Monoclonal antibody

ZZura Bio Inc

Tibulizumab is one of 37 biologic programs targeting Systemic Sclerosis. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Systemic SclerosisActive, not recruiting

Systemic SclerosisPhase 2

Active, not recruiting

Competition

Competitive Landscape

165 competitors in Systemic Sclerosis

#DrugCompanyPhaseTrials

Fludara

Sanofi

Phase 3

3 2

Actemra

Roche

Phase 3

3 3

Medrol

Pfizer

Phase 3

3 4

Opsumit

Johnson & Johnson

Phase 3

2 5

Rinvoq

AbbVie

Phase 3

1 6

Cysteine Hydrochloride

Novartis

Phase 3

1 7

Ofev

Boehringer Ingelheim

Phase 3

1 8

UPLIZNA

HHorizon Therapeutics Ireland DAC

Phase 3

1 9

Neupogen

EEastern Cooperative Oncology Group

Phase 3

1 10

Esbriet

LLegacy Health System

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 2Active, not recruiting

Hidradenitis Suppurativa (HS)

NCT06993610

Q1 2028

Phase 2Recruiting

Systemic Sclerosis

NCT06843239

Clinical

Trials by Indication[1]

Primary Sjogren's Syndrome1 trial

BAFF/IL-17 Bispecific Antibody Treatment in Subjects With Primary Sjogren's Syndrome

Withdrawn·MMatthew C. Baker·Phase 2/3·NCT04563195

Systemic Sclerosis1 trial

Tibulizumab Systemic Sclerosis Understanding and Response Evaluation (TibuSURE)

Recruiting·ZZura Bio Inc·Phase 2·NCT06843239·80 enrolled

Hidradenitis Suppurativa (HS)1 trial

A Phase 2, Multi-Center Study Consisting of a Randomized, Placebo-Controlled Period, Followed by an Open-Label Extension Period to Assess the Efficacy, Safety, and Tolerability of Tibulizumab in Adults With Hidradenitis Suppurativa

Active, not recruiting·ZZura Bio Inc·Phase 2·NCT06993610·225 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Tibulizumab. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Tibulizumab compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Tibulizumab. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Zura Bio Inc company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Monoclonal antibody[2]
Highest Phase: Phase 2[1]
Company: ZZura Bio Inc

Tibulizumab

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Q1 2028

Trials by Indication[1]

Primary Sjogren's Syndrome1 trial

Systemic Sclerosis1 trial

Hidradenitis Suppurativa (HS)1 trial

References

Drug Info

Quick Facts

Related News